Aveo expects to $86.3 million in IPO - The Associated Press PDF Print
Aveo expects to $86.3 million in IPOThe Associated PressInc. The company's lead product candidate is Tivozanib, which is now in last-stage development as a renal cell cancer treatment.Aveo jumps into IPO game with plans to raise $86M FierceBiotechAveo Pharmaceuticals Files To Sell Up To $86.3M In IPO Wall Street Journal all 88 news articles »

... read more

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.